John Sperzel III, Sharon Klugewicz

May 31, 2017

Chembio Diagnostics CEO John Sperzel III has taken a medical leave of absence, the firm said. No further details were given. In his absence Sharon Klugewicz will be the acting CEO. She is also Chembio's president of the Americas region, and previously was its COO and VP of QA/QC . 

More Like This

Jul 17, 2018

Laurence Klotz

miR Scientific (formerly miR Diagnostics) has appointed Laurence Klotz as chief medical officer. Klotz currently serves as chairman of the World Urologic Oncology Federation. He has also been a member of the Institute of Medical Science and a graduate faculty member at the University of Toronto since 2005, and a professor of surgery at the University of Toronto since 2000.

Jul 17, 2018

Matthew Walls

Former Genedrive CEO Matthew Walls has been appointed chairman of UK women's healthcare firm Concepta, effective immediately. The former chairman, Adam Reynolds, will move into a non-executive role. Walls was also chief executive of patient behavioral change company Atlantis Healthcare Group and chairman of The Fertility Partnership in the UK. 

Concepta also appointed Peter Dines as a non-executive director, effective immediatley. Dines is the COO and head of life sciences and biosciences at Marcia Technologies, Concepta's major shareholder. Mark Wyatt is stepping down as a non-executive director to focus on other business interests, Concepta said. The company was founded in 2013 with a focus on helping women with fertility issues and has developed a proprietary platform and fertility product for home self-testing or for the doctor's office. 

Jul 13, 2018

Leena Das-Young

Guardant Health has appointed Leena Das-Young to serve as general manager of its LUNAR program. In her new role, Das-Young will oversee all work applying Guardant Health's technology and database of more than 70,000 clinical Guardant360 assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection.

Prior to joining Guardant, Das-Young was vice president and head of the late phase strategy development group at Pfizer's oncology group, where she was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in various commercial roles responsible for several successful launches at both Pfizer and Bayer.  She holds BS and Doctor of Pharmacy degrees from Purdue University.

Jul 13, 2018

Jinjie Hu

Laboratory for Advanced Medicine announced today that it has appointed Jinjie Hu as the firm's Chief Regulatory Officer. Hu currently serves as President and principal consultant at Axteria BioMed Consulting, and as senior consultant for Biologics Consulting Group. Hu has also served as World Health Organization advisor for its diagnostic pre-qualification program, as well as the International Network Committee chair of the FDA alumni association. 

Jul 12, 2018

Johnson Chiang, Rixun Fang

Johnson Chiang has been appointed chief technology officer and Rixun Fang director of assay development at Alveo Technologies.

Chiang was previously head of systems integration and molecular biology at Foundation Medicine. He also held senior management positions at Life Technologies and at Thermo Fisher Scientific. Prior to that, he led molecular diagnostic product development projects at Applied MEMS, Applied Biosystems, and Cepheid.

Fang previously led several molecular biology research and IVD development projects at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific.

Jul 12, 2018

Robert Mittelstaedt Jr., Adam Schechter

Laboratory Corporation of America announced that Robert Mittelstaedt, Jr., lead independent director, will retire from the LabCorp board of directors at the conclusion of his current term on May 9, 2019. Adam Schecter has been elected to serve as lead independent director effective Jan. 2, 2019, so that he and Mittelstaedt can work together on a smooth transition.

Mittelstaedt will retire from the board pursuant to the company's mandatory retirement policy, which provides that directors are not eligible for re-election at regularly scheduled annual shareholder meetings after the age of 75. Mittelstaedt became a director of LabCorp in 1996 and shared board executive sessions beginning in 2006. He has served as lead independent director since 2009. He has also served on various board committees including serving as chair of the nominating and corporate governance committee, chair of the compensation committee and member of the audit committee.

Jul 12, 2018

Freenome Impact Advisory Board

Freenome has announced the creation of what it calls its Impact Advisory Board, a group tasked with helping the company optimize strategies, including those that will guide its first commercial launch of a blood-based, artificial intelligence-derived genomic test for the early detection of colorectal cancer.

The new board includes NDA Partners' Alberto Gutierrez, a former 25-year veteran of the US Food and Drug Administration, who will be tasked with guiding regulatory strategy. Joining Gutierrez are two experts on payor strategy: Louis Jacques, chief clinical officer of ADVI Health and former head of the Centers for Medicare and Medicaid Services' Coverage and Analysis Group; and Sherie Smalley, senior medical director of medical policy at UPMC Health Plan.

It also includes clinical development advisors with expertise in gastroenterology, including Douglas Robertson from the US Multi-Society Task Force of Colorectal Cancer.

Jul 11, 2018

Nicholas Parker

Nicholas Parker has joined at-home-based testing firm EverlyWell as its first chief technology officer. Prior to joining the firm, Parker was CTO at uShip, a shipping marketplace based in Austin, Texas. EverlyWell, also headquartered in Austin, offers a variety of tests including general wellness, hbA1C, sexual health, and food sensitivity tests. 

Jul 10, 2018

Fayyaz Memon

Immunexpress has appointed Fayyaz Memon as the firm's VP of regulatory affairs and quality. With over 25 years of experience in the life science industry, Memon has previously served in leadership positions at Asuragen, Qiagen, PrimeraDx, Thermo Fisher Scientific, Digene, SmithKline Beecham, and Johnson & Johnson.

Jul 10, 2018

Violaine Mélen, Stéphane Cruveiller

PathoQuest has appointed Violaine Mélen as its head of quality assurance and regulatory affairs. In the new position, Mélen will oversee the maintenance of product quality and compliance in line with the firm's quality management system, while also leading the firm's regulatory strategies. She has more than 12 years of experience in regulatory affairs, quality assurance, and clinical affairs within the biotech and pharmaceutical industries. Mélen previously worked at Bio-Rad Laboratories where she was responsible for implementing risk management procedures with a specific focus on infectious disease.

In addition, PathoQuest has appointed Stéphane Cruveiller as its chief technology information officer. As CTIO, Cruveiller will be responsible for the technical aspects of the firm's bioinformatics pipeline and alignment information technology-related development initiatives with its business goals. Cruveiller previously served as team leader at the François Jacob Institute of Biology - Genoscope of the French Alternative Energies and Atomic Energy Commission at the Laboratory of Bioinformatics Analyses for Genomics and Metabolism.

Jul 09, 2018

George Golumbeski, Onaiza Cadoret-Manier, Fred Kohler, Angela Lai

Grail has added to its executive team, hiring George Golumbeski as president, Onaiza Cadoret-Manier as chief commercial officer, and Fred Kohler as vice president of people. The firm has also promoted Angela Lai to chief technology officer.

Golumbeski most recently served as executive vice president of business development for Celgene, and currently serves on the boards of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. He will replace Ken Drazan as president, who has stepped down to work on helping early-stage start-up firms secure funding. Drazan will continue to serve as an advisor to Grail. Golumbeski will also join Grail's board of directors.

Cadoret-Manier joins Grail from Genentech where she was vice president of the respiratory franchise. Previously, she held various senior management positions overseeing sales and marketing for several products at Genentech, Pfizer, Amylin Pharmaceuticals, and Quest Diagnostics.

Kohler has joined Grail from Roche, where he most recently led transformation work. Kohler previously worked at Autodesk and Juniper Networks, where he held a variety of human resources roles.

Lai has served as vice president of clinical technology at Grail since July 2016. She was responsible for building Grail's software systems team and supporting the company's clinical studies.

Jul 06, 2018

Lyn Rees, Stephen Little, Keng Hsu

Lyn Rees has become CEO of Premaitha Health, replacing Stephen Little, who is now the company's executive vice chairman. Rees joins Premaitha from BBI Group, where he was most recently CEO.

In addition, Keng Hsu has become Premaitha's chief operating officer for Asia. He used to be CFO of Yourgene Bioscience, which Premaitha acquired last year.

Furthermore, Alan Chang has stepped down as non-executive director of Premaitha to focus on other business interests.

Jul 03, 2018

Paul Kinnon

Paul Kinnon has been appointed CEO of PredictImmune in Cambridge, UK. He previously held leadership positions at Transgenomic, ZyGem, Life Technologies, Guava Technologies, and Cellomics. Kinnon started his career as an analytical chemist at Smithkline French & Beckman Research, a predecessor of GlaxoSmithKline.

Jun 28, 2018

Amy Abernethy

CareDx has appointed Amy Abernethy to its board of directors. Abernethy is chief medical officer, CSO, and senior vice president for oncology for Flatiron Health. She also serves on the board for Athenahealth. Before joining Flatiron, Abernethy was a professor of medicine at Duke University School of Medicine and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. She maintains an adjunct professorship with Duke.

Jun 26, 2018

Brian Brille, Michael Sullivan, Nicholas Nelson

Caris Life Sciences appointed Brian Brille as vice chairman, Michael Sullivan as chief commercial officer, and Nicholas Nelson as chief business officer. Brille will be responsible for corporate and business development, M&A, and capital markets. He has more than 25 years of experience as a senior financial services executive. Most recently, he was president of Asia Pacific for Bank of America Merrill Lynch. Before that, he was global head of corporate and investment banking at Bank of America. 

Before joining Caris, Sullivan was at Roche Diagnostics where he was most recently senior vice president, general manager, and business unit lifecycle leader of the company's core oncology franchise. He also held commercial leadership roles at Johnson & Johnson Ortho-Clinical Diagnostics and Abbott Laboratories' diagnostics division. 

Nelson was vice president of commercial and corporate development at Trovagene before joining Caris. He also spent 10 years at Illumina in R&D, technical service, and sales.